AP
VRTX icon

Anchyra Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Anchyra Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
620
+18
+3% +$7.98K 0.07% 236
2026
Q1 		$269K Buy
602
+33
+6% +$15.4K 0.08% 223
2025
Q4 		$258K Buy
+569
New +$245K 0.08% 220

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Anchyra Partners's VRTX Position: Q2 2026 in Review

Anchyra Partners increased its Vertex Pharmaceuticals (VRTX) stake by 3% in Q2 2026, buying an estimated $7.98K and bringing the position to 620 shares worth $308K. The position accounts for 0.07% of the portfolio, ranked #236.

Anchyra Partners first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,014 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Anchyra Partners held 620 shares of Vertex Pharmaceuticals worth $308K as of Q2 2026.
  • Anchyra Partners bought 18 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.98K.
  • Vertex Pharmaceuticals made up 0.07% of Anchyra Partners's portfolio in Q2 2026, its #236 holding.
  • Anchyra Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,014 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Anchyra Partners's 13F filing for Q2 2026, filed 23 Jul 2026.